drugset / Trial / NCT02786667

Non Motors Aspects in De Novo Parkinson's Disease

NCT02786667

Phase 3 Unknown 199 enrolled University Hospital, Grenoble
RandomizedParallel-groupTriple-blindTreatment

Summary

Clinical description and pathophysiological study of recently diagnosed untreated patients with Parkinson's Disease. Effect of a dopamine agonist (rotigotine) on apathy in de novo patients with Parkinson disease: A controlled, randomized, double blind study.

Timeline

Start
2012-06
Primary completion
2017-10-15
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 8 mg

Indications